癌变·畸变·突变 ›› 2025, Vol. 37 ›› Issue (2): 140-146,152.doi: 10.3969/j.issn.1004-616x.2025.02.008

• 论著 • 上一篇    下一篇

人CD8α分子特异性核酸适配体的筛选与鉴定

李安然, 孙红光, 申晨晨, 阿孜姑丽·阿布都卡迪尔, 马艳   

  1. 新疆医科大学公共卫生学院劳动卫生与环境卫生教研室, 新疆 乌鲁木齐 830011
  • 收稿日期:2024-12-02 修回日期:2025-01-17 出版日期:2025-03-30 发布日期:2025-04-11
  • 通讯作者: 马艳
  • 作者简介:李安然,E-mail:15927193393@163.com。
  • 基金资助:
    新疆维吾尔自治区自然科学基金面上项目(2022D01C445)

Screening and characterization of nucleic acid aptamers specific for the human CD8α molecule

LI Anran, SUN Hongguang, SHEN Chenchen, ARZIGUL·Abdukadir, MA Yan   

  1. Labour and Environmental Hygiene Department, School of Public Health, Xinjiang Medical University, Urumqi 830011, Xinjiang, China
  • Received:2024-12-02 Revised:2025-01-17 Online:2025-03-30 Published:2025-04-11

摘要: 目的:筛选并鉴定与人CD8α分子特异性结合的核酸适配体(Apt)。方法:以携带6×组氨酸标签的重组人CD8α蛋白为筛选靶点,设计81 nt的随机文库,利用SELEX技术进行核酸适配体筛选。将富集的文库进行高通量测序及聚类分析,以最高丰度序列为例,通过斑点杂交法和流式细胞术验证其与CD8α蛋白和CD8+细胞的特异结合情况。利用流式细胞术测定候选核酸适配体与CD8α蛋白和CD8+细胞结合的亲和常数(Kds)。最后以正常人外周血淋巴细胞为模型,利用流式细胞术初步评价候选核酸适配体以及现有技术公开的CD8核酸适配体在临床样本中鉴定CD8+淋巴细胞的临床应用能力,并检测Apt 1与人外周血样本中CD8+淋巴细胞的结合位点是否和CD8抗体与CD8α蛋白的结合位点一致。结果:富集文库经高通量测序后,获得了42 803个有效序列读数, 经Clustal Omega在线软件聚类分析,按丰度排序将前10条序列作为候选核酸适配体,分别命名为Apt 1~Apt 10。10个候选核酸适配体序列中均存在1个高度保守的一致序列(CGTGAGGAGCTTGAAATCC)。其中,Apt 1具有典型的茎环结构(△G=-12.61 kcal/mol),能与CD8α蛋白和CD8+细胞系高特异性结合。10个候选核酸适配体Apt 1~Apt 10均可与CD8α蛋白和CD8+细胞高亲和力结合,亲和常数(Kds)均在纳摩尔水平。与商业化CD8抗体及现有技术公开的CD8核酸适配体相比,候选核酸适配体均能有效鉴定人外周血样本中的CD8+淋巴细胞,Apt 1与人外周血样本中CD8+淋巴细胞的结合位点不同于CD8抗体的结合位点。结论:成功筛选出与人CD8α分子强亲和力和高特异性结合的核酸适配体,可为后续开发针对CD8靶点的临床诊断和治疗方法奠定基础。

关键词: 核酸适配体, 指数富集的配体系统进化技术, CD8, 高通量测序, 人外周血淋巴细胞

Abstract: OBJECTIVE:To identify nucleic acid aptamers that bind specifically to human CD8α molecules. METHODS:A recombinant human CD8α protein with a 6×histidine tag was used as the screening target,and a randomized library of 81 nt was designed for nucleic acid aptamer screening by SELEX technology. The enriched libraries were subjected to high-throughput sequencing and cluster analysis,and the highest abundance sequences were used to verify their specific binding to CD8α protein and CD8+ cells by spot hybridization and flow cytometry. The affinity constants (Kds) of all aptamer candidates were determined using flow cytometry. Finally,normal human peripheral blood lymphocytes were used as a model,and flow cytometry was used to preliminarily evaluate the clinical application of these candidates by prior art to identify CD8+ lymphocytes in clinical samples,and to detect whether the binding site of Apt 1 and CD8+ lymphocytes was the same as that of CD8 antibody and CD8α protein. RESULTS:The enriched library was sequenced by high-throughput sequencing and 42 803 valid sequence reads were obtained,which were clustered and analyzed by Clustal Omega online software. The top 10 sequences were ranked in order of abundance as the candidate nucleic acid aptamers,which were named as Apt 1-Apt 10,respectively. A highly conserved concordant sequence was present in all candidate sequences (CGTGAGGAGCTTGAAATCC). Among them,Apt 1 had a typical stem-loop structure (ΔG=-12.61 kcal/mol) and bound with high specificity to CD8α protein and CD8+ cells. In addition,all 10 sequences bound with high affinity to CD8α protein and CD8+ cells,and the affinity constants (Kds) were at the namor level. Compared with commercial CD8 antibodies and CD8 aptamers disclosed in prior art,the candidate aptamers effectively identified CD8+ lymphocytes in human peripheral blood samples,and the binding sites of Apt 1 and CD8+ lymphocytes in human peripheral blood samples were different from those of CD8 antibodies. CONCLUSION:Successful screening of nucleic acid aptamers that bound with high affinity and specificity to human CD8α molecules laid the foundation for the subsequent development of clinical diagnostic and therapeutic approaches against CD8 targets.

Key words: nucleic acid aptamer, SELEX, CD8, high-throughput sequencing, human peripheral blood lymphocytes

中图分类号: